Atopic Dermatitis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis, DelveInsight | Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Han

Atopic Dermatitis Pipeline constitutes 100+ key companies continuously working towards developing 110+ Atopic Dermatitis treatment therapies, analyzes DelveInsight.

Atopic Dermatitis Overview:

Atopic dermatitis (AD), also known as eczema, is a chronic skin condition that typically begins in childhood but can occur at any age. It is the most common type of skin inflammation, characterized by itchiness, redness, and rashes. The condition is often linked to genetics, an overactive immune system, infections, allergies, and exposure to irritants. People with moderate-to-severe AD frequently have other allergic conditions like asthma, hay fever, and food allergies. It is the most prevalent chronic skin disease in children.

The development of AD is complex, involving a combination of factors such as a weakened skin barrier, immune system imbalances, IgE-mediated hypersensitivity, and environmental triggers. Mutations in the filaggrin gene, which affect skin hydration and barrier function, have been associated with more severe forms of AD. Additionally, an imbalance in immune cell responses, particularly a shift from Th1 to Th2 cytokines, plays a role in the condition. Inflammation in AD is driven by an accumulation of immune cells, including various types of dendritic cells, which contribute to the skin's inflammatory response.

The exact cause of AD remains unclear, but it is understood to involve an interplay of immune dysregulation, genetic mutations, and environmental factors that disrupt the skin's protective barrier. This leads to dry, itchy skin prone to irritants and inflammation. Although AD is not contagious, it results in intensely itchy skin lesions.
Request for a detailed insights report on Atopic Dermatitis pipeline insights @ https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Atopic Dermatitis Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Atopic Dermatitis Therapeutics Market.

Key Takeaways from the Atopic Dermatitis Pipeline Report

DelveInsight's Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
In April 2024, Dermavant Sciences announced that the U.S. Food and Drug Administration (FDA) has accepted the Supplemental New Drug Application (sNDA) for VTAMA as a topical treatment for atopic dermatitis.
Key Atopic Dermatitis companies such as Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others are evaluating new drugs for Atopic Dermatitis to improve the treatment landscape.
Promising Atopic Dermatitis pipeline therapies in various stages of development include Tapinarof, Etrasimod, B244, Lirentelimab, QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., and others.

Atopic Dermatitis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Atopic Dermatitis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Atopic Dermatitis market.

Download our free sample page report on Atopic Dermatitis pipeline insights @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Atopic Dermatitis Emerging Drugs

Tapinarof: Dermavant Sciences
Etrasimod: Pfizer
B244: AOBiome
Lirentelimab: Allakos Inc.
QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Atopic Dermatitis Companies

Over 100 key companies are working on developing therapies for atopic dermatitis. Among them, Dermavant Sciences has drug candidates for atopic dermatitis in the most advanced stage, Phase III.

DelveInsight's report covers around 110+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Atopic Dermatitis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Atopic Dermatitis Therapies and Key Companies: Atopic Dermatitis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Atopic Dermatitis Pipeline Therapeutic Assessment
• Atopic Dermatitis Assessment by Product Type
• Atopic Dermatitis By Stage
• Atopic Dermatitis Assessment by Route of Administration
• Atopic Dermatitis Assessment by Molecule Type

Download Atopic Dermatitis Sample report to know in detail about the Atopic Dermatitis treatment market @ Atopic Dermatitis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Atopic Dermatitis Current Treatment Patterns
4. Atopic Dermatitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Atopic Dermatitis Late-Stage Products (Phase-III)
7. Atopic Dermatitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Atopic Dermatitis Discontinued Products
13. Atopic Dermatitis Product Profiles
14. Atopic Dermatitis Key Companies
15. Atopic Dermatitis Key Products
16. Dormant and Discontinued Products
17. Atopic Dermatitis Unmet Needs
18. Atopic Dermatitis Future Perspectives
19. Atopic Dermatitis Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Atopic Dermatitis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.